Short answer
Elevance Health (ELV) filed its Q3 2026 10-Q quarterly report on Oct 21, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $51.4B (up 1.4% year over year) with net income of $1.4B.
Q3 2026 key financials · XBRL
- Revenue
- $51.4B
- +1.4% YoY · +1.9% QoQ
- Net income
- $1.4B
- +14.8% YoY · −6.7% QoQ
- Operating margin
- 2.5%
- EPS (diluted)
- $6.28
- +17.6% YoY · −6.7% QoQ
Source: XBRL data from the Elevance Health (ELV) Q3 2026 10-Q on SEC EDGAR. USD.
Elevance Health Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly operating revenue $50,440, up 0.7% from $50,087 YoY
- Operating margin 2.5% vs 2.6% YoY, benefit expense ratio 90.6% vs 91.3%
- Best segment: CarelonRx revenue $11,599, up 5.5%, operating margin 5.3% vs 5.1%
- Worst segment: Health Benefits operating gain $3,489, down 20.3%, margin 1.0% vs 1.4%
- Operating cash flow $7,512 vs $4,206; investments $2,303, buybacks $1,688, dividends $1,122, debt repayments $900 year-to-date
- Near-term headwinds: elevated Medicaid medical costs, lower membership, expired APTCs, regulatory changes and Medicare Advantage Star Ratings declining to 49% alts
Risk Factors
- No risk factors section provided, limiting comparison with the 2025 Form 10-K
- Seasonal healthcare demand and competitive conditions may distort interim results versus full-year performance
- Foreign-currency translation exposure from subsidiaries operating outside the United States
- Medical membership concentration: approximately 44.9 million members as of September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Elevance Health quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.